2BBBullish & Bearish
Lyell Immunopharma, Inc. (LYEL) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 52 out of 100.
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors.
Lyell Immunopharma, Inc.’s current 2BB score is 52 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 65 | High |
| Momentum | 68 | Improving |
| Financial strength | 15 | Very Weak |
| Quality | 98 | Very Strong |
| Risk | 58 | Moderate |
| Headquarters | South San Francisco, California, United States |
| Founded | 2018 |
| Employees | 161 |
| 52-week range | $7.20 – $45.00 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-03-12 | — | -2.1828 | — | $1,275.00 |
| 2026-11-09 | — | -2.1148 | — | $2,376.00 |
| 2026-08-10 | — | -2.0648 | — | $3,906.00 |
| 2026-05-11 | — | -2.1094 | — | $6,456.00 |